Drug intelligence / Profile preview

aspirin + atorvastatin + clopidogrel + simvastatin

Development stage: Discontinued
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

This is a combination of four medications: two statins (atorvastatin and simvastatin) and two antiplatelet agents (aspirin and clopidogrel). The combination is used to prevent cardiovascular events such as heart attacks and strokes. Aspirin and clopidogrel work as antiplatelet agents that prevent blood clots from forming by inhibiting platelet aggregation. Atorvastatin and simvastatin are HMG-CoA reductase inhibitors (statins) that lower cholesterol levels by blocking the enzyme needed for cholesterol production in the liver.

Targets

P2Y12 (Purinergic P2Y12 receptor)PGHS-1 (Prostaglandin G/H Synthase 1)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)

Beyond the preview

Go deeper on aspirin + atorvastatin + clopidogrel + simvastatin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on aspirin + atorvastatin + clopidogrel + simvastatin.

Explore the full profile